Recent Company News

• 07:04 PM ET Nov 26, 2025
  

  Hutchmed to present new and updated data from several studies of compounds discovered at 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting (HK$22.38, 0.00)

• 08:44 PM ET Nov 05, 2025
  

  StreetAccount Sector Summary - China Healthcare October Recap

• 07:06 PM ET Nov 04, 2025
  

  Hutchmed completes patient enrollment for SAFFRON global phase III trial of ORPATHYS and TAGRISSO combination (HK$24.30, 0.00)

• 08:47 AM ET Nov 04, 2025
  

  Transcript Intelligence: Hutchmed at Deutsche Bank Depositary Receipts Virtual Investor Conference (HK$24.30, 0.00)

• 08:50 AM ET Oct 29, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:16 PM ET Oct 28, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 10:09 PM ET Oct 24, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 03:11 PM ET Oct 24, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 26-Oct

• 08:03 PM ET Oct 22, 2025
  

  Hutchmed presents preclinical HMPL-A251 data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (HK$23.82, 0.00)

• 12:13 AM ET Oct 13, 2025
  

  Hutchmed to present results from phase III part of FRUSІCA-2 trial for renal cell carcinoma on 17-Oct at ESMO Congress (HK$23.52, -1.22)